SCHEMBL692107

SCHEMBL692107

[c]1nc2ccccc2nc1-c1ncc2ccccc2n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.45
KDM4E B2RXH2 1/20 0.40
GPR3 P46089 1/20 0.40
MAPT P10636 3/20 0.37
NPC1 O15118 1/20 0.37
LMNA P02545 1/20 0.37
RECQL P46063 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
EGFR P00533 1/20 0.36
HTR3A P46098 1/20 0.34
HRH4 Q9H3N8 1/20 0.34
ALDH1A1 P00352 2/20 0.33
GLA P06280 1/20 0.33
HPGD P15428 1/20 0.33
ACHE P22303 1/20 0.33
NQO2 P16083 1/20 0.32
PDE10A Q9Y233 1/20 0.32
FDPS P14324 1/20 0.31
MGAM O43451 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9843907 0.78 ALDH1A1 (0.40) KDM4EGPR3MAPTLMNARAB9A
SCHEMBL30198446 0.77 CYP1A2 (0.60) CYP1A2KDM4EGPR3MAPTNPC1
SCHEMBL1672650 0.77 CYP1A2 (0.60) CYP1A2KDM4EGPR3MAPTNPC1
SCHEMBL30527184 0.77 CYP1A2 (0.60) CYP1A2KDM4EGPR3MAPTNPC1
SCHEMBL4778401 0.75 CYP1A2 (0.46) CYP1A2KDM4EGPR3MAPTNPC1
SCHEMBL14099190 0.74 CYP1A2 (0.53) CYP1A2KDM4EGPR3MAPTNPC1
SCHEMBL13911016 0.73 CYP1A2 (0.56) CYP1A2KDM4EGPR3MAPTNPC1
SCHEMBL528392 0.71 NPC1 (0.47) CYP1A2KDM4EGPR3MAPTNPC1
SCHEMBL11060746 0.71 TDP1 (0.40) KDM4EMAPTLMNASMN1; SMN2ALDH1A1
SCHEMBL1434260 0.71 RAB9A (0.46) CYP1A2KDM4EMAPTNPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118339155-A Novel compound and organic light emitting device comprising the same 株式会社LG化学 2024-07-12 CN disclosed
CN-113166120-B Compound and organic light emitting device comprising the same 株式会社LG化学 2024-07-12 CN disclosed
CN-113227082-B Compound and organic light emitting device using the same 株式会社LG化学 2024-07-12 CN disclosed
CN-113039184-B Compound and organic light emitting device comprising the same 株式会社LG化学 2024-07-12 CN disclosed
CN-118339158-A Novel compound and organic light emitting device comprising the same 株式会社LG化学 2024-07-12 CN disclosed
CN-112789742-B Organic light emitting device 株式会社LG化学 2024-07-09 CN disclosed
CN-113166112-B Compound and organic light emitting device comprising the same 株式会社LG化学 2024-07-05 CN disclosed
CN-113498412-B Compound and organic light emitting device comprising the same 株式会社LG化学 2024-07-02 CN disclosed
CN-115135652-B Novel compound and organic light emitting device including the same 株式会社LG化学 2024-07-02 CN disclosed
CN-113727980-B Compound and organic light emitting device comprising the same 株式会社LG化学 2024-06-28 CN disclosed
EP-1326606-A2 EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS PFIZER PHARMACEUTICALS INC. (JP) 2003-07-16 EP disclosed
EP-1326864-A2 ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER PHARMACEUTICALS INC. (JP) 2003-07-16 EP disclosed
US-20030130277-A1 Pyrazoloquinolinone derivatives as protein kinase C inhibitors KAWAMURA KIYOSHI (JP) 2003-07-10 US disclosed
EP-1325921-A2 Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators Pfizer Inc. (US) 2003-07-09 EP disclosed
EP-1310498-A2 Pyrazoloquinolinone derivatives as protein kinase C inhibitors PFIZER INC. (US) 2003-05-14 EP disclosed
WO-2002060896-A1 ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES PFIZER PRODUCTS INC. (US) 2002-08-08 WO disclosed
US-20020107273-A1 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents ASKAT INC. (JP) 2002-08-08 US disclosed
US-20020077329-A1 EP4 receptor inhibitors to treat rheumatoid arthritis PFIZER PHARMACEUTICALS INC. (JP) 2002-06-20 US disclosed
WO-2002032422-A2 EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS PFIZER PHARMACEUTICALS INC. (JP) 2002-04-25 WO disclosed
WO-2002032900-A2 ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER PHARMACEUTICALS INC. (JP) 2002-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130277-A1 Pyrazoloquinolinone derivatives as protein kinase C inhibitors PRKCB, PRKCA, PRKCG CYP1A2 3063/4885KDM4E 1349/4885GPR3 907/4885
US-20020107273-A1 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents PTGS1, PTGS2, OPRM1 CYP1A2 139/4885KDM4E 3701/4885GPR3 393/4885
US-20020077329-A1 EP4 receptor inhibitors to treat rheumatoid arthritis PTGER4, PTGER1, PTGER2 CYP1A2 1271/4885KDM4E 1206/4885GPR3 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.